Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04877613 · ClinicalTrials.gov registry record · Phase 1
GFRα4 CAR T Cells in MTC Patients
A Phase 1 study of Metastatic Medullary Thyroid Cancer and Recurrent Thyroid Gland Medullary Carcinoma, sponsored by University of Pennsylvania.
- Active
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT04877613 is a Phase 1 study of Metastatic Medullary Thyroid Cancer and Recurrent Thyroid Gland Medullary Carcinoma that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04877613, a Phase 1 study of Metastatic Medullary Thyroid Cancer and Recurrent Thyroid Gland Medullary Carcinoma, is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MTC).
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG single dose of CART-GFRa4 cells
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2021-08-19 |
| Est. Completion | 2039-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04877613
The ClinicalTrials.gov registry entry for NCT04877613 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Medullary Thyroid Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT04877613 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04877613 about?
NCT04877613 is a clinical study titled "GFRα4 CAR T Cells in MTC Patients". This is an open-label phase 1 study to assess the safety and feasibility of autologous T cells expressing a single-chain scFv targeting GFRα4 with tandem TCR/CD3ζ and 4-1BB (TCRζ/4-1BB) co-stimulatory domains (referred to as "CART-GFRa4 cells") in patients with incurable medullary thyroid cancer (MT...
What is the current status of trial NCT04877613?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2021-08-19. Estimated completion is 2039-06-01.
What conditions does trial NCT04877613 study?
This clinical trial studies the following conditions: Metastatic Medullary Thyroid Cancer, Recurrent Thyroid Gland Medullary Carcinoma.
What interventions are being tested in trial NCT04877613?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), single dose of CART-GFRa4 cells (DRUG).
Who is sponsoring clinical trial NCT04877613?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04877613 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Medullary Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Metastatic Medullary Thyroid Cancer
All registered trials for this condition
Recurrent Thyroid Gland Medullary Carcinoma
All registered trials for this condition
Pennsylvania
All trials with a study site in Pennsylvania
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.